Abstract
Objectives: Botulinum neurotoxin type A (BoNT A) is widely used in treatment of cerebral palsy (CP)1. Recently a preparation free of complexing proteins (Xeomin®) has been issued, but is not yet usable on-label in childhood. Methods: Case-report. We show preliminary data of 6 children aged 4 to 17 years, suffering uni- or bilateral cerebral palsy (GMFCS level 1–5°). Patients got intramuscular injections of BoNT A in other formula before. Because of secondary decrease of effect preparation was changed to off-label-used BoNT A Xeomin®. Results: Dosage applied was 10–76 MU/kg (max. 1.020 MU total), using multi-muscle-option. Injection was always performed while patients were in deep analgosedation using s-ketamin and midazolam (i.v. or rectal). All patients showed good painrelief and decrease of spasticity after injection. No relevant sideeffects occurred. Conclusions: In several conditions while treating children with spastic syndromes like CP we are in need for treatment-alternatives for conventional BoNT A (Botox®). BoNT free of complexing proteins (Xeomin®) is a possible alternative in cases when off-label-use is not a conditio-sine-qua-non, because Xeomin® seemed to bee as safe, dosage seemed to be equivalent to Botox®. 1 Heinen, F. eta al.: Botulinumtoxin fur Kinder mit Zerebralparesen: 10-Punkte-Tabelle, 2007. Ein interdisziplinarer deutscher Konsensus. Monatsschr Kinderheilkd 2007; 155: 537–543.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
